scholarly journals Carbon nanoparticles suspension injection for photothermal therapy of xenografted human thyroid carcinoma in vivo

MedComm ◽  
2020 ◽  
Vol 1 (2) ◽  
pp. 202-210
Author(s):  
Yuanfang Huang ◽  
Guangfu Zeng ◽  
Qian Xin ◽  
Jinmei Yang ◽  
Cheng Zeng ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Photothermal Therapy ◽  
Carbon Nanoparticles ◽  
Human Thyroid ◽  
Nanoparticles Suspension

Reestablishment of In Vitro and In Vivo Iodide Uptake by Transfection of the Human Sodium Iodide Symporter (hNIS) in a hNIS Defective Human Thyroid Carcinoma Cell Line

Thyroid ◽  
2000 ◽  
Vol 10 (11) ◽  
pp. 939-943 ◽  
Author(s):  
Jan W.A. Smit ◽  
Janny P. Schröder-van der Elst ◽  
Marcel Karperien ◽  
Ivo Que ◽  
Gabri van der Pluijm ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Cell Line ◽  
Sodium Iodide ◽  
Carcinoma Cell ◽  
Human Thyroid ◽  
Sodium Iodide Symporter ◽  
Iodide Uptake ◽  
Thyroid Carcinoma Cell

pH-Responsible fluorescent carbon nanoparticles for tumor selective theranostics via pH-turn on/off fluorescence and photothermal effect in vivo and in vitro

Nanoscale ◽  
2018 ◽  
Vol 10 (5) ◽  
pp. 2512-2523 ◽  
Author(s):  
Eun Bi Kang ◽  
Jung Eun Lee ◽  
Zihnil Adha Islamy Mazrad ◽  
Insik In ◽  
Ji Hoon Jeong ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Photothermal Therapy ◽  
Carbon Nanoparticles ◽  
Fluorescence Probes ◽  
Photothermal Effect ◽  
Turn On ◽  
Fluorescent Carbon Nanoparticles ◽  
Tumor Selective

Here we designed the functionalized FNP as “switch-on” fluorescence probes to sense intracellular cancer cells and controllable photothermal therapy (PTT) in vivo and in vitro.

scholarly journals Cetuximab-Conjugated Perfluorohexane/Gold Nanoparticles for Low Intensity Focused Ultrasound Diagnosis Ablation of Thyroid Cancer Treatment

2020 ◽  
Author(s):  
Yue Ma ◽  
Lingling Wang ◽  
Haixia Li ◽  
Wen Cheng ◽  
Xiulan Zheng ◽  
...  
Keyword(s):  
Gold Nanoparticles ◽  
Thyroid Cancer ◽  
Thyroid Carcinoma ◽  
Cancer Treatment ◽  
Focused Ultrasound ◽  
Ultrasound Diagnosis ◽  
Human Thyroid ◽  
Rat Serum ◽  
Low Intensity

Abstract Chemotherapeutic efficacy plays a significant role in the development of nanotheranostic systems for drug delivery in tumor cells. In this study, we demonstrate the self-assembly of C225 conjugate, Perfluorohexane/Gold Nanoparticles (Au-PFH-NPs), which results in low-intensity focused ultrasound diagnosis ablation of thyroid cancer treatment. Cetuximab-Conjugated Perfluorohexane/Gold Nanoparticles (C-Au-PFH-NPs) showed excellent stability in water, PBS, and 20% rat serum. Transmission electron microscopy images revealed the effective construction of C-Au-PFH-NPs with commonly spherical assemblies. The incubation of C625 thyroid carcinoma with C-Au-PFH-NPs triggered apoptosis, which was confirmed by flow cytometry analysis. The C-Au-PFH-NPs showed remarkable antitumor efficacy in human thyroid carcinoma xenografts. The histopathological results additionally confirm the achieved outcomes. Furthermore, we successfully examined the efficiency of C-Au-PFH-NPs when using the thyroid carcinoma low-intensity focused ultrasound (LIFUS) diagnostic imaging in vivo. These findings are clear for LIFUS agents with high performing images. It is also identified that different therapeutic purposes will have extensive potential for future biomedical purposes.

Backscatter coefficient estimation in human thyroid carcinoma In vivo

2016 ◽  
Vol 140 (4) ◽  
pp. 3137-3137 ◽  
Author(s):  
Julien Rouyer ◽  
Rosa Laimes ◽  
Claudia Salazar ◽  
Joseph Pinto ◽  
Jorge Guerrero ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Human Thyroid ◽  
Backscatter Coefficient ◽  
Coefficient Estimation

A High-Throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma

2021 ◽  
Author(s):  
Ying C Henderson ◽  
Abdallah S R Mohamed ◽  
Anastasios Maniakas ◽  
Yunyun Chen ◽  
Reid T Powell ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Growth Inhibition ◽  
High Throughput ◽  
Anaplastic Thyroid Carcinoma ◽  
Human Thyroid ◽  
Tumor Growth Inhibition ◽  
In Vivo Models ◽  
Systemic Agents ◽  
Pdx Models

Abstract Background Despite the use of aggressive multimodality treatment, most anaplastic thyroid carcinoma (ATC) patients die within a year of diagnosis. Although the combination of BRAF and MEK inhibitors has recently been approved for use in BRAF-mutated ATC, they remain effective in a minority of patients who are likely to develop drug resistance. There remains a critical clinical need for effective systemic agents for ATC with a reasonable toxicity profile to allow for rapid translational development. Methods & Methods Twelve human thyroid cancer cell lines with comprehensive genomic characterization were used in a high-throughput screening (HTS) of 257 compounds to select agents with maximal growth inhibition. Cell proliferation, colony formation, orthotopic thyroid models, and patient-derived xenograft models (PDX) were used to validate the selected agents. Results Seventeen compounds were effective and docetaxel, LBH-589, and pralatrexate were selected for additional in vitro and in vivo analysis as they have been previously approved by the FDA for other cancers. Significant tumor growth inhibition (TGI) was detected in all tested models treated with LBH-589; pralatrexate demonstrated significant TGI in the orthotopic papillary thyroid carcinoma model and two PDX models; docetaxel demonstrated significant TGI only in the context of mutant TP53. Conclusions HTS identified classes of systemic agents which demonstrate preferential effectiveness against aggressive thyroid cancers, particularly those with mutant TP53. Preclinical validation in both orthotopic and PDX models, which are accurate in vivo models mimicking tumor microenvironment, may support initiation of early phase clinical trials in non-BRAF mutated or refractory to BRAF/MEK inhibition ATC.

scholarly journals Cetuximab-Conjugated Perfluorohexane/Gold Nanoparticles for Low Intensity Focused Ultrasound Diagnosis Ablation of Thyroid Cancer Treatment

2020 ◽  
Author(s):  
Yue Ma ◽  
Lingling Wang ◽  
Haixia Li ◽  
Wen Cheng ◽  
Xiulan Zheng ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Carcinoma ◽  
Cancer Treatment ◽  
Focused Ultrasound ◽  
Ultrasound Diagnosis ◽  
Human Thyroid ◽  
Rat Serum ◽  
High Performing ◽  
Low Intensity

Abstract Chemotherapeutic efficacy can be significantly developed nanotheranostics systems of drug delivery in tumor cells. In this work, we have demonstrated that the self-assembled by C225 conjugates Au-PFH-NPs (C-Au-PFH-NPs) for low intensity focused ultrasound diagnosis ablation of thyroid cancer treatment. C-Au-PFH-NPs have shown excellent stability in water, PBS and 20% rat serum. Transmission electron microscopy (TEM) images also exposed the effective construction of C-Au-PFH-NPs with commonly spherical sized assemblies. The incubation of the C625 thyroid carcinoma with C-Au-PFH-NPs triggers apoptosis, which was confirmed by the flowcytometry analysis. The C-Au-PFH-NPs, with remarkably displays the potent antitumor efficacy in a human thyroid carcinoma xenografts. A histopathological result reveals that precisely achieved to additional confirm these outcomes. Further, we successfully examined the efficiency of C-Au-PFH-NPs when used the thyroid carcinoma low intensity focused ultrasound diagnosis imaging (LIFUS) in vivo. These findings clearable for LIFUS agents with high performing image and different therapeutic purpose will have extensive possible for the future biomedical purposes.

AZD5153, a novel BRD4 inhibitor, suppresses human thyroid carcinoma cell growth in vitro and in vivo

2018 ◽  
Vol 499 (3) ◽  
pp. 531-537 ◽  
Author(s):  
Kun Xu ◽  
Dexuan Chen ◽  
Dong Qian ◽  
Shihu Zhang ◽  
Yi Zhang ◽  
...  
Keyword(s):  
Cell Growth ◽  
Thyroid Carcinoma ◽  
Carcinoma Cell ◽  
Human Thyroid ◽  
Thyroid Carcinoma Cell

Ultrastructural modification of cellular interactions in cancer tumor

1978 ◽  
Vol 36 (2) ◽  
pp. 318-319
Author(s):  
N. P. Dmitrieva
Keyword(s):  
Cancer Cells ◽  
Human Thyroid ◽  
Adjacent Cell ◽  
Main Role ◽  
Cellular Interactions ◽  
Electron Microscopic ◽  
Cancer Tumor ◽  
Normal Human ◽  
Characteristic Features

One of the most characteristic features of cancer cells is their ability to metastasia. It is suggested that the modifications of the structure and properties of cancer cells surfaces play the main role in this process. The present work was aimed at finding out what ultrastructural features apear in tumor in vivo which removal of individual cancer cells from the cell population can provide. For this purpose the cellular interactions in the normal human thyroid and cancer tumor of this gland electron microscopic were studied. The tissues were fixed in osmium tetroxide and were embedded in Araldite-Epon.In normal human thyroid the most common type of intercellular contacts was represented by simple junction formed by the parallelalignment of adjacent cell membranees leaving in between an intermembranes space 15-20 nm filled with electronlucid material (Fig. 1a). Sometimes in the basal part of cells dilatations of the intercellular space 40-50 nm wide were found (Fig. 1a). Here the cell surfaces may form single short microvilli.

scholarly journals Characterization of LDD-2633 as a Novel RET Kinase Inhibitor with Anti-Tumor Effects in Thyroid Cancer

2021 ◽  
Vol 14 (1) ◽  
pp. 38
Author(s):  
Hyo Jeong Lee ◽  
Pyeonghwa Jeong ◽  
Yeongyu Moon ◽  
Jungil Choi ◽  
Jeong Doo Heo ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Carcinoma ◽  
Kinase Inhibitor ◽  
Point Mutations ◽  
Carcinoma Cells ◽  
Medullary Thyroid ◽  
Potent Inhibition ◽  
Kinase Inhibitory Activity

Rearranged during transfection (RET), a receptor tyrosine kinase, is activated by glial cell line-derived neurotrophic factor family ligands. Chromosomal rearrangement or point mutations in RET are observed in patients with papillary thyroid and medullary thyroid carcinomas. Oncogenic alteration of RET results in constitutive activation of RET activity. Therefore, inhibiting RET activity has become a target in thyroid cancer therapy. Here, the anti-tumor activity of a novel RET inhibitor was characterized in medullary thyroid carcinoma cells. The indirubin derivative LDD-2633 was tested for RET kinase inhibitory activity. In vitro, LDD-2633 showed potent inhibition of RET kinase activity, with an IC50 of 4.42 nM. The growth of TT thyroid carcinoma cells harboring an RET mutation was suppressed by LDD-2633 treatment via the proliferation suppression and the induction of apoptosis. The effects of LDD-2633 on the RET signaling pathway were examined; LDD-2633 inhibited the phosphorylation of the RET protein and the downstream molecules Shc and ERK1/2. Oral administration of 20 or 40 mg/kg of LDD-2633 induced dose-dependent suppression of TT cell xenograft tumor growth. The in vivo and in vitro experimental results supported the potential use of LDD-2633 as an anticancer drug for thyroid cancers.

Sign in / Sign up

Export Citation Format

Share Document